Clear, clinician-reviewed guides to GLP-1 therapy, weight care and the questions everyone asks first — written in plain language, with no pressure to buy anything.
Check your BMI and see where you'd sit against the clinical criteria — in about thirty seconds.
What's common, what's not, and the simple habits that keep the first few weeks comfortable.
What generic availability means, the patent timeline, and how to tell quality sources from grey-market ones.
The three quiet, simultaneous ways these medications change appetite and digestion.
Which private plans help, what public coverage exists, and how to submit for reimbursement.
A week-by-week look at titration, what changes when, and the milestones to expect.
Same molecule, two different approvals. We break down dosing, indications and what it means for weight care.
Dual-hormone tirzepatide versus single-hormone semaglutide — how the mechanisms and results differ.
Two weight-management approvals compared head to head on dosing, trial data and availability.
The essentials, in the order most people ask them.
The science, in plain language
Interactive — check in 30 seconds
What to expect, week by week
Mechanism, safety and managing the early weeks.
Hunger, digestion & blood sugar
What's common, what's not
Compounding, patents & quality
Neutral, side-by-side breakdowns of the options people weigh most.
Same molecule, two approvals
Dual-hormone vs single-hormone
Two weight-management approvals
What treatment costs in Canada, and how to get help paying for it.
Private plans, public coverage, claims
Branded vs generic pricing
Enter your height and weight to see your BMI and where you'd sit against the clinical eligibility criteria. No account, no email — just a starting point for a conversation with a clinician.
Check my eligibilityFor information only. The guides in Wexi Learn are educational and are not a substitute for personalized medical advice, diagnosis or treatment. GLP-1 medications are available by prescription only and are not appropriate for everyone; eligibility, dosing and safety are always determined by a licensed clinician who reviews your full history. Always read your patient information leaflet and speak with your Wexi care team before starting, stopping or changing any therapy. Trademarks. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Wexi is not affiliated with, endorsed by or sponsored by these companies. Brand names are used for identification and comparison only.